Danish researchers identified a microRNA shown to predict whether a patient with colorectal cancer would be resistant to oxaliplatin treatment, a discovery that holds promise of improving both current treatment options and development of future treatment strategies.
Addition of Elotuzumab to Bortezomib/Dexamethasone Improves Survival in Relapsed/Refractory Multiple MyelomaAugust 16, 2016
The addition of elotuzumab to bortezomib/dexamethasone appears to increase progression-free survival in relapsed/refractory multiple myeloma (RRMM).
Risks for severe toxicities in obese patients receiving dose-dense chemotherapy are associated with measures used to determine dose, according to a retrospective evaluation of select participants in the GAIN study.
Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) plus ponatinib appears to be superior to hyper-CVAD plus dasatinib for the frontline treatment of patients with Philadelphia chromosome-positive ALL.
At my current clinic, hydration and mannitol are administered before premedications on a cisplatin regimen; at previous clinic, premeds and hydration were administered before mannitol. Does it make a difference?
Cognitive decline associated with adjuvant chemotherapy was more likely to occur in older patients, particularly those whose treatment included docetaxel.
Chemotherapy agents are sometimes required to be administered in a specific sequence. What factors influence the need to follow a specific sequence?
Fasting during chemotherapy treatment may increase the presence of cancer-killing T cells, according to recent study data.
Dab2 is an endocytic adaptor and tumor suppressor whose expression occurs during the epithelial-mesenchymal transition, which is mediated by TGF-beta. This study sought to understand how Dab2 regulates apoptosis.
Telomere length is predictive for determining which children treated for AML are at highest risk for delayed recovery, a finding that may have significant implications for treatment-related morbidity and mortality.
Balanced is improved and fall risk is reduced among cancer patients with peripheral neuropathy who participated in Argentine tango dancing as a form of therapy.
A first-line triplet chemoimmunotherapy regimen comprised of paclitaxel, capecitabine, and bevacizumab followed by capecitabine and bevacizumab alone as maintenance therapy is highly active with a manageable safety profile in patients with triple-negative breast cancer.
Omitting bleomycin from the treatment regimen for Hodgkin lymphoma in patients with negative findings on an interim PET scan led to a lower incidence of pulmonary toxic effects without significantly lowering treatment efficacy.
What factors should be considered when calculating an adequate postmedication flush to deliver complete, accurate doses of small-volume IV medications to our patients?
Resistance to therapy through adaptation poses a major hurdle for cancer therapy. Bioengineers addressed this by creating a single nanoparticle that comprises a synergistic drug pair that shuts down mechanisms of resistance to a degree that has not been previously achieved.
Immunotherapy for advanced ovarian cancer more effectively treats tumors when administered immediately after chemotherapy. Sequential chemoimmunotherapy could improve disease control in stage IIIC/IV tubo-ovarian HGSC.
Assessment and Monitoring of Patients Receiving Chemotherapy for Multiple Myeloma: Strategies to Improve OutcomesJuly 01, 2016
[Blood and Lymphatic Cancer: Targets and Therapy] This research reviews updates in the diagnosis and management of multiple myeloma, and provides for assessment and monitoring strategies for patients receiving chemotherapy for multiple myeloma.
[Cancer Management and Research] This review focuses on dronabinol and its role in the treatment of chemotherapy-induced nausea and vomiting (CINV).
Adjuvant chemotherapy in patients with stage Ib non-small cell lung cancer improved overall survival and 5-year overall survival.
Aligning chemotherapy administration to the time of day when the body is most awake benefits the effectiveness of the treatment, as shown in a mouse model.
A new material was developed to soak up chemotherapy drugs after the tumor is treated and before they can circulate throughout the body, potentially limiting the side effects of chemotherapy.
PEG-IFN did not improve improve outcomes for patients with melanoma compared with IFN. Furthermore, patients receiving PEG-IFN were more likely to discontinue treatment due to toxicity.
In patients with completely resected stage IB NSCLC, adjuvant chemotherapy is associated with improved survival regardless of tumor size.
Combining a laboratory ultrasound technique called sonoporation with the commercially available chemotherapy compound gemcitabine increases the porosity of pancreatic cells with microbubbles and helps get the drug into cancer cells.
Despite the increased risk, patients whose pancreatic cancer tumor has grown to encompass critical blood vessels can be candidates for surgery. Data on efforts to fine-tune a protocol for these patients were presented at the SSAT 57th Annual Meeting.
NETTER-1 trial results of the somatostatin analogue peptide, 177Lu-DOTA0-Tyr3-octreotate (177Lu-Dotatate), suggest a potential survival benefit in patients with advanced midgut neuroendocrine tumors (NETs), attendees at the ASCO 2016 Annual Meeting were told.
In patients with advanced hepatocellular carcinoma (HCC), adding doxorubicin to sorafenib did not improve overall survival or progression-free survival and resulted in higher toxicity compared to sorafenib alone, results from a phase 3 study presented at the ASCO 2016 Annual Meeting have shown.
First results from the phase 3 CRITICS study found no significant difference in overall survival between postoperative chemotherapy and chemoradiotherapy in patients with resectable gastric cancer, according to a study presented at the ASCO 2016 Annual Meeting.
Daratumumab + Bortezomib/Dexamethasone: Reduced Risk of Disease Progression Seen in Relapsed or Refractory Multiple MyelomaJune 06, 2016
Adding daratumumab to bortezomib and dexamethasone was associated with a 61% reduction in risk of disease progression in patients with relapsed or refractory multiple myeloma (RRMM), according to results of the phase 3 CASTOR study presented in a plenary session at the ASCO 2016 Annual Meeting.
Adding Temozolomide to Radiotherapy Improves Survival in Elderly Patients With Newly Diagnosed GlioblastomaJune 06, 2016
The addition of temozolomide to standard short-course radiation therapy significantly improved both overall and progression-free survival in elderly patients with newly diagnosed glioblastoma, results from the first study to test this combination in this age group concluded in a plenary presentation at the ASCO 2016 Annual Meeting.
- PMPS: A Common Late Effect of Surgery and Radiation for Breast Cancer
- Breast Cancer Tumors Often a Composite of Tumor Types, Enhancing Treatment Resistance
- Physical Activity May Reduce Mortality by 44% in Patients With Breast Cancer
- Hormone Receptor Test Results in DCIS Core Needle Biopsy Not Used, Not Needed
- Daratumumab Plus Len-Dex an Encouraging Combo for Multiple Myeloma
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Triple-Drug Therapy Produces Response in Triple-Negative Breast Cancer, Mouse Study Shows
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Study Supports Increased Role for Surgery in Multimodality Therapy for Early Stage SCLC
- Recently Discovered microRNA Controls Response to Oxaliplatin in Colorectal Cancer
- Nurses Are Key to Referrals to Inpatient Integrative Medicine Services
- Daratumumab Combo Improves PFS in Relapsed/Refractory Myeloma
- Poor Compliance to Adjuvant Chemo Linked to Poorer Survival in Rectal Cancer
- Users Support Indoor Tanning Device Age Restrictions, Stronger Health Warnings, But Not Total Ban
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|